Multiple Myeloma Hub
Is the treatment of high-risk SMM the way for achieving the cure?
Sep 23, 2021
Dr. María-Victoria Mateos discusses the progression from MGUS to MM, risk stratification for SMM, and clinical trials showing benefits of treating high-risk SMM. Early treatment of SMM is key in her cure roadmap, with two curative approaches in clinical trials.
13:05
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Early treatment of high-risk SMM can delay progression to MM.
- Identifying high-risk patients through refined clinical models is crucial for optimal management.
Deep dives
Cure Definition and Comparative Survival Rates
The podcast episode delves into the evolving definition of cure in multiple myeloma, emphasizing the need to achieve disease-free survivors with an annual death rate similar to that of the general population. While some hematological diseases like lymphomas are considered curable, there exists a significant survival gap in myeloma compared to the expected rates. The complexity of myeloma, varied disease presentations in patients, and the importance of early detection and intervention are highlighted as crucial factors in addressing this gap.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
